NCT01890577 - Study of South African Dialysis Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions

Chronic Kidney Disease, Receiving Dialysis

Interventions

DRUG

Aranesp

Observational study; minimum single dose of Aranesp required for eligibility; no protocol-specified regimen; study must not influence normal clinical practice.

Trial Locations (7)

1709

Research Site, Roodepoort

1821

Research Site, Lenasia

4001

Research Site, Durban

4083

Research Site, Glenwood

4320

Research Site, Umhlanga

7800

Research Site, Cape Town

8300

Research Site, Kimberley